Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Publikováno v: The Lancet Infectious Diseases. 13:401-408

Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1969bae89fa7165a9e21f5367bdac35b
https://doi.org/10.1016/s1473-3099(13)70033-1

Zobrazit plný text záznamu

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

Autor: William T. Symonds, Kris V. Kowdley, Christy M. Hebner, David R. Nelson, Maribel Rodriguez-Torres, Eric Lawitz, E. DeJesus, Deyuan Jiang, Melanie Cornpropst, J. Lalezari, Efsevia Albanis, M. Mader, John G. McHutchison, M.M. Berrey

Publikováno v: Journal of Hepatology. 58:663-668

Background & Aims Sofosbuvir (formerly GS-7977) is a pyrimidine nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B polymerase. We assessed the safety, tolerability, antiviral activity, and pharmacokinetics of sofosbuvir plus pegylated-in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90139a85380b63faf96fe0cc06969ad6
https://doi.org/10.1016/j.jhep.2012.11.018

Zobrazit plný text záznamu

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

Autor: A. Mathias, M.M. Berrey, William T. Symonds, J. Denning, B. Gao, Hongmei Mo, Melanie Cornpropst, Maribel Rodriguez-Torres, Eric Lawitz

Publikováno v: Journal of Viral Hepatitis. 20:699-707

Sofosbuvir and GS-0938 are distinct nucleotide analogues with activity against hepatitis C virus (HCV) in vitro. We evaluated the antiviral activity and safety of sofosbuvir and GS-0938 alone and in combination in HCV genotype 1 patients. In this dou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f7a743ddea0faf48094a20a0a194c13
https://doi.org/10.1111/jvh.12091

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects

Autor: M.M. Berrey, William T. Symonds, Melanie Cornpropst, Jill Denning, Stephen D. Flach

Publikováno v: Antimicrobial Agents and Chemotherapy. 57:1201-1208

To investigate the pharmacokinetics, safety, and tolerability of GS-9851 (formerly PSI-7851), a new nucleotide analog inhibitor of hepatitis C virus (HCV), we conducted a double-blind, parallel, placebo-controlled, randomized, single-ascending-dose s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f563241892297b7b7e658c4272db660
https://doi.org/10.1128/aac.01262-12

Zobrazit plný text záznamu

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

Autor: Catherine A.M. Stedman, M.M. Berrey, Evguenia S. Svarovskaia, William T. Symonds, Xiao Ding, Edward Gane, R. Hindes, Robert H. Hyland

Publikováno v: New England Journal of Medicine. 368:34-44

The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c346cdbab3f6a8ce9f4775a43eb48db7
https://doi.org/10.1056/nejmoa1208953

Zobrazit plný text záznamu

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

Autor: Alan Kosaka, Hyunsoon Kang, Abel De La Rosa, Aren Ewing, M.M. Berrey, Nick Cammack, Isabel Najera, A. Seshaadri, J.M. Yan, Bill Symonds, Sophie Le Pogam

Publikováno v: The Journal of Infectious Diseases. 202:1510-1519

Introduction. RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log 10 IU/mL, respectively, associated with 1500-mg doses t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e3179c9fb4f6d9d8af2c825023ff74
https://doi.org/10.1086/656774

Zobrazit plný text záznamu

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects

Autor: Anne Shachoy-Clark, M.M. Berrey, Vicky Otto, Kimberly K. Adkison, Stephen C. Piscitelli, Yu Lou, Lei Fang

Publikováno v: British Journal of Clinical Pharmacology. 62:336-344

Aims This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady-state pharmacokinetics (PK) of aplaviroc (APL), a CYP3A4 substrate, in healthy subjects. Methods In Part 1, APL PK was determined in eight subjects

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f95a438035fc470a081f69c56434a0
https://doi.org/10.1111/j.1365-2125.2006.02661.x

Zobrazit plný text záznamu

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

Autor: Anne N. Nafziger, Ivy Song, M.M. Berrey, Kimberly K. Adkison, Lei Fang, Stephen C. Piscitelli, Joseph S. Bertino, Brendan M. Johnson, Yu Lou, Julie Borland

Publikováno v: The Journal of Clinical Pharmacology. 46:577-587

Aplaviroc is a novel CCR5 antagonist, a class of compounds under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus infection. A modified Cooperstown 5 +1 cocktail was used to assess the drug interaction potenti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb9f0c978debe95d29ac648ad23024d
https://doi.org/10.1177/0091270006287291

Zobrazit plný text záznamu

Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects

Autor: Kathy O'Mara, Stephen C. Piscitelli, Anne Shachoy-Clark, Lei Fang, M.M. Berrey, Kimberly K. Adkison, Yu Lou

Publikováno v: Antimicrobial Agents and Chemotherapy. 49:2802-2806

873140 is a novel CCR5 antagonist with potent in vitro anti-human immunodeficiency virus (HIV) activity. This study was a double-blind, randomized, placebo-controlled, single- and repeat-dose escalation investigation of the safety, pharmacokinetics,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8e06532ec45208623dd22c86c11d450
https://doi.org/10.1128/aac.49.7.2802-2806.2005

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání